Imunon (IMNN) Income from Continuing Operations (2010 - 2026)
Imunon's (IMNN) quarterly Income from Continuing Operations came in at 4370406.0 in Q1 2026, down 2.41% YoY from 4478148.7 in Q1 2025, and down 0.67% on a QoQ basis from 4341210.0 in Q4 2025.
Imunon (IMNN) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Imunon (IMNN) has 17 years of Income from Continuing Operations data on file, last reported at 4370406.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 2.41% year-over-year to 4370406.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 16413260.0 (up 12.87% YoY) and the FY2025 annual result came in at 91274049.0, down 390.19% from the prior year.
- Income from Continuing Operations eased to 4370406.0 in Q1 2026, from 4341210.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 3583891.0 in Q3 2025 to a low of 11075793.0 in Q4 2022.
- A 5-year average of 5313248.71 and a median of 5158253.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 170.67% — and 2023, when it jumped 45.38%.
- Tracing IMNN's Income from Continuing Operations over 5 years: stood at 11075793.0 in 2022, then jumped by 45.38% to 6049330.0 in 2023, then surged by 30.65% to 4195501.0 in 2024, then slipped by 3.47% to 4341210.0 in 2025, then slipped by 0.67% to 4370406.0 in 2026.
- The last three Income from Continuing Operations figures came in at 4370406.0 (Q1 2026), 4341210.0 (Q4 2025), and 3583891.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Imunon | 8.42 Mn | 8.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.37 Mn |
| Dec 31, 2025 | -4.34 Mn |
| Sep 30, 2025 | -3.58 Mn |
| Jun 30, 2025 | -4.12 Mn |
| Mar 31, 2025 | -4.27 Mn |
| Dec 31, 2024 | -4.20 Mn |
| Sep 30, 2024 | -5.22 Mn |
| Jun 30, 2024 | -5.16 Mn |
| Mar 31, 2024 | -5.09 Mn |
| Dec 31, 2023 | -6.05 Mn |
| Sep 30, 2023 | -3.67 Mn |
| Jun 30, 2023 | -5.33 Mn |
| Mar 31, 2023 | -5.61 Mn |
| Dec 31, 2022 | -11.08 Mn |
| Sep 30, 2022 | -6.17 Mn |
| Jun 30, 2022 | -6.09 Mn |
| Mar 31, 2022 | -5.98 Mn |
| Dec 31, 2021 | 15.67 Mn |
| Sep 30, 2021 | -5.21 Mn |
| Jun 30, 2021 | -5.29 Mn |